Overview

Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether the early and continuous addition of bevacizumab for up to 30 months to the standard chemotherapy is more effective than the early and continuous addition of bevacizumab for up to 15 months.

Phase:

Phase 3

Details

Lead Sponsor:

AGO Study Group

Collaborators:

ARCAGY/ GINECO GROUP
Nordic Society for Gynaecologic Oncology
Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Paclitaxel